- Home
- EVOK vs KTTA Comparison
EVOK vs KTTA Comparison
Compare EVOK & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- KTTA
- Stock Information
- Founded
- EVOK 2007
- KTTA 2020
- Country
- EVOK United States
- KTTA United States
- Employees
- EVOK N/A
- KTTA 4
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- KTTA Health Care
- Exchange
- EVOK Nasdaq
- KTTA Nasdaq
- Market Cap
- EVOK 5.4M
- KTTA 5.5M
- IPO Year
- EVOK 2013
- KTTA 2021
- Fundamental
- Price
- EVOK $5.12
- KTTA $0.70
- Analyst Decision
- EVOK
- KTTA
- Analyst Count
- EVOK 0
- KTTA 0
- Target Price
- EVOK N/A
- KTTA N/A
- AVG Volume (30 Days)
- EVOK 432.5K
- KTTA 201.4K
- Earning Date
- EVOK 11-06-2025
- KTTA 11-12-2025
- Dividend Yield
- EVOK N/A
- KTTA N/A
- EPS Growth
- EVOK N/A
- KTTA N/A
- EPS
- EVOK N/A
- KTTA N/A
- Revenue
- EVOK $12,794,859.00
- KTTA N/A
- Revenue This Year
- EVOK $57.38
- KTTA N/A
- Revenue Next Year
- EVOK $59.57
- KTTA N/A
- P/E Ratio
- EVOK N/A
- KTTA N/A
- Revenue Growth
- EVOK 70.02
- KTTA N/A
- 52 Week Low
- EVOK $1.94
- KTTA $0.65
- 52 Week High
- EVOK $12.32
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- EVOK 49.82
- KTTA 41.14
- Support Level
- EVOK $5.00
- KTTA $0.74
- Resistance Level
- EVOK $5.27
- KTTA $0.81
- Average True Range (ATR)
- EVOK 0.22
- KTTA 0.06
- MACD
- EVOK -0.05
- KTTA -0.01
- Stochastic Oscillator
- EVOK 38.91
- KTTA 4.84
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).